-transparent.png){kind=logo}
Thirty-four normocalcaemic women with multiple osteolytic bone metastases from breast cancer were randomly allocated to treatment with disodium dichloromethylene diphosphonate (Cl2MDP) 1600 mg/day orally (17) or placebo (17) for 3-9 months. Fasting urinary hydroxyproline/creatinine and calcium/creatinine ratios declined in the Cl2MDP group but not in the placebo group. Four patients in the placebo group died from hypercalcaemia. New bone metastases were more common in patients on placebo and these patients also required more analgesic drugs than those on Cl2MDP. Cl2MDP seemed to reduce bone pain and bone resorption and prevent the development of hypercalcaemia caused by osteolytic metastases. The formation of new bone metastases and the growth of old ones seemed to be retarded by Cl2MDP.
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
February 1984,
Presse medicale (Paris, France : 1983),
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
September 1987,
Archives of internal medicine,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
August 2012,
Acta orthopaedica Belgica,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
January 2018,
World journal of nuclear medicine,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
March 1998,
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
November 1955,
Nederlands tijdschrift voor geneeskunde,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
January 1978,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
April 2000,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
July 2015,
Urology,
I Elomaa, and
C Blomqvist, and
P Gröhn, and
L Porkka, and
A L Kairento, and
K Selander, and
C Lamberg-Allardt, and
T Holmström
June 2000,
Cancer,
